Abstract
While India is a favorable destination for conducting clinical trials, recent reports of alleged deaths due to serious adverse events and inadequate compensation have led regulators in India to take measures and initiatives. Some examples include introducing guidance documents, advisory committees, a compensation clause in informed consent forms, clinical trial registries, registration of contract research organizations and ethics committees, pharmacovigilance programs, notices for periodic safety update report submission, notices to ethics committees, and inspections for streamlining the regulations. These steps will further ensure the accountability of the stakeholders involved while India continues to conduct trials.